Form 4 for CRL Charles River Laboratories
Accepted 2023-11-15 00:00:00 ET · period of report 2023-11-14 · accession 0001127602-23-027415 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-15 | 2023-11-14 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | P - Purchase | $178.05 | +5,620 | 202.6K | +3% | +$1.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-14 | P | A | 5,620 | $178.05 | 202,643 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $177.99 to $178.11. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |